Trimetazidine and Bisoprolol to Treat Angina in Symptomatic Patients: Post Hoc Analysis From the CHOICE-2 Study.
Angina
Bisoprolol
Real-world clinical setting
Trimetazidine
Journal
Cardiology and therapy
ISSN: 2193-8261
Titre abrégé: Cardiol Ther
Pays: England
ID NLM: 101634495
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
23
09
2020
pubmed:
29
11
2020
medline:
29
11
2020
entrez:
28
11
2020
Statut:
ppublish
Résumé
Angina is the cardinal symptom of chronic coronary syndrome (CCS), which is the leading cause of death worldwide. As such, the control of angina is important. The current guidelines recommend beta blockers (BB) or calcium channel blockers to reduce angina, yet many patients with stable angina remain symptomatic. It has been suggested that combining trimetazidine (TMZ), an anti-ischemic agent, with a BB is beneficial for symptomatic patients. Bisoprolol, a BB, is often used to treat patients with CCS, yet no data are currently available regarding the efficacy of bisoprolol combined with TMZ in patients who remain symptomatic despite receiving bisoprolol. The aim of this post-hoc analysis of the CHOICE-2 study was to evaluate the efficacy and safety of TMZ 35 mg twice daily in combination with different bisoprolol doses in symptomatic patients with stable angina patients receiving hemodynamic therapy in a real-world clinical setting. This analysis involved 221 patients (mean [± standard deviation] age 64.8 ± 8.9 years) with stable angina. The mean number of weekly angina episodes gradually fell from 6.2 ± 5.3 at inclusion (M0) to 1.5 ± 1.9 at 6 months after treatment initiation (M6) with combined TMZ-bisoprolol therapy (P < 0.001). The number of patients assessed to be angina-free increased almost sixfold from 5.4% (12/221) at M0 to 33.9% (74/221) at M6. Exercise capacity improved, as measured by walking distance, from 308 ± 207 m at M0 to 497 ± 253 m at M6 (P < 0.05). The number of patients with Canadian Cardiovascular Society class 1 angina increased by tenfold during the study, whereas those with class 3 angina decreased by threefold. The TMZ-bisoprolol combination is a rapidly effective treatment for reducing the frequency of angina attacks and the use of short-acting nitrates in patients with stable angina in a real-world clinical setting. The benefits of this combination therapy was observed as early as 2 weeks after treatment initiation and the treatment was well tolerated. ISRCTN identifier: ISRCTN65209863.
Identifiants
pubmed: 33247333
doi: 10.1007/s40119-020-00202-6
pii: 10.1007/s40119-020-00202-6
pmc: PMC8126526
doi:
Types de publication
Journal Article
Langues
eng
Pagination
161-173Références
GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151–210.
Poole-Wilson PA, Voko Z, Kirwan BA, de Brouwer S, Dunselman PH, Lubsen J. Clinical course of isolated stable angina due to coronary heart disease. Eur Heart J. 2007;28(16):1928–35.
doi: 10.1093/eurheartj/ehm198
Povsic TJ, Broderick S, Anstrom KJ, et al. Predictors of long-term clinical endpoints in patients with refractory angina. J Am Heart Assoc. 2015;4(2):e001287.
Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126(25):e354-471.
pubmed: 23166211
Ferrari R, Ford I, Greenlaw N, et al. Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: data from the contemporary CLARIFY registry. Eur J Prev Cardiol. 2015;22(8):1056–65.
doi: 10.1177/2047487314547652
Steg PG, Greenlaw N, Tendera M, et al. Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry. JAMA Intern Med. 2014;174(10):1651–9.
doi: 10.1001/jamainternmed.2014.3773
Huqi A, Morrone D, Guarini G, Capozza P, Orsini E, Marzilli M (2016) Stress testing after complete and successful coronary revascularization. Can J Cardiol 32(8):986.e23–9.
Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360(3):213–24.
Maron DJ, Spertus JA, Mancini GB, et al. Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial. Am J Cardiol. 2009;104(8):1055–62.
doi: 10.1016/j.amjcard.2009.05.056
Steg PG, Ferrari R, Ford I, et al. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS ONE. 2012;7(5):e36284.
doi: 10.1371/journal.pone.0036284
Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86(5):580–8.
doi: 10.1161/01.RES.86.5.580
Fragasso G, Perseghin G, De Cobelli F, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006;27(8):942–8.
doi: 10.1093/eurheartj/ehi816
Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther. 1990;4(Suppl 4):853–9.
doi: 10.1007/BF00051292
Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol. Results of a randomized, double-blind, multicentre study (TRIMPOL II). Eur Heart J. 2001;22(24):2267–74.
doi: 10.1053/euhj.2001.2896
Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol. 1994;37(3):279–88.
doi: 10.1111/j.1365-2125.1994.tb04276.x
Hu B, Li W, Xu T, Chen T, Guo J. Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta-analysis of randomized, controlled trials. Clin Cardiol. 2011;34(6):395–400.
doi: 10.1002/clc.20888
Danchin N, Marzilli M, Parkhomenko A, Ribeiro JP. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology. 2011;120(2):59–72.
doi: 10.1159/000332369
Zhao Y, Peng L, Luo Y, et al. Trimetazidine improves exercise tolerance in patients with ischemic heart disease: a meta-analysis. Herz. 2016;41(6):514–22.
doi: 10.1007/s00059-015-4392-2
Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011;97(4):278–86.
doi: 10.1136/hrt.2010.208751
Zhang L, Lu Y, Jiang H, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol. 2012;59(10):913–22.
doi: 10.1016/j.jacc.2011.11.027
Zhou X, Chen J. Is treatment with trimetazidine beneficial in patients with chronic heart failure? PLoS ONE. 2014;9(5):e94660.
doi: 10.1371/journal.pone.0094660
Lopatin YM, Rosano GM, Fragasso G, et al. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. Int J Cardiol. 2016;203:909–15.
doi: 10.1016/j.ijcard.2015.11.060
Michaelides AP, Spiropoulos K, Dimopoulos K, Athanasiades D, Toutouzas P. Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Invest. 1997;13(1):8–14.
doi: 10.2165/00044011-199713010-00002
Ruzyllo W, Szwed H, Sadowski Z, et al. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. Curr Med Res Opin. 2004;20(9):1447–54.
doi: 10.1185/030079904X2637
Glezer M. Real-world evidence for the antianginal efficacy of trimetazidine from the russian observational CHOICE-2 study. Adv Ther. 2017;34(4):915–24.
doi: 10.1007/s12325-017-0490-2
Kloner RA, Chaitman B. Angina and Its Management. J Cardiovasc Pharmacol Ther. 2017;22(3):199–209.
doi: 10.1177/1074248416679733
Ellison KE, Gandhi G. Optimising the use of beta-adrenoceptor antagonists in coronary artery disease. Drugs. 2005;65(6):787–97.
doi: 10.2165/00003495-200565060-00006
Sabido M, Thilo H, Guido G. Long-term effectiveness of bisoprolol in patients with angina: a real-world evidence study. Pharmacol Res. 2019;139:106–12.
doi: 10.1016/j.phrs.2018.10.031
European Society of Cardiology (ESC). 2019 Guidelines on chronic coronary syndromes. ESC clinical practice guidelines 2019. https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Chronic-Coronary-Syndromes .
Tendera M, Fox K, Ferrari R, et al. Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry. Int J Cardiol. 2014;176(1):119–24.
doi: 10.1016/j.ijcard.2014.06.052
Boyle RM, Bray CL, Naqvi N, Croxson RS, Cruickshank JM. A comparison of once and twice daily atenolol for angina pectoris. Int J Cardiol. 1983;3(1):25–35.
doi: 10.1016/0167-5273(83)90058-X
Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27(10):1153–8.
doi: 10.1093/eurheartj/ehi705
Al-Lamee R, Thompson D, Dehbi H-M, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31–40.
doi: 10.1016/S0140-6736(17)32714-9
Peng S, Zhao M, Wan J, Fang Q, Fang D, Li K. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. Int J Cardiol. 2014;177(3):780–5.
doi: 10.1016/j.ijcard.2014.10.149
Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–16.
doi: 10.1056/NEJMoa070829
Weisz G, Genereux P, Iniguez A, et al. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10014):136–45.
doi: 10.1016/S0140-6736(15)00459-6
Peri-Okonny PA, Patel KK, Jones PG, et al. Low diastolic blood pressure is associated with angina in patients with chronic coronary artery disease. J Am Coll Cardiol. 2018;72(11):1227–32.
doi: 10.1016/j.jacc.2018.05.075
Vidal-Petiot E, Greenlaw N, Ford I, et al. Relationships between components of blood pressure and cardiovascular events in patients with stable coronary artery disease and hypertension. Hypertension. 2018;71(1):168–76.
doi: 10.1161/HYPERTENSIONAHA.117.10204